Marc E. Key
About
Marc E. Key is a scholar working on Molecular Biology, Immunology and Oncology.
According to data from OpenAlex, Marc E. Key has authored 31 papers receiving a total of 3.2k indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Molecular Biology, 14 papers in Immunology and 8 papers in Oncology. Recurrent topics in Marc E. Key's work include Immunotherapy and Immune Responses (8 papers), Cancer Research and Treatments (7 papers) and Cancer Immunotherapy and Biomarkers (7 papers). Marc E. Key is often cited by papers focused on Immunotherapy and Immune Responses (8 papers), Cancer Research and Treatments (7 papers) and Cancer Immunotherapy and Biomarkers (7 papers). Marc E. Key collaborates with scholars based in United States, Australia and India. Marc E. Key's co-authors include Krishan L. Kalra, Shan‐Rong Shi, James W. Fett, James E. Talmadge, Karen A. Olson, Michael G. Hanna, I. J. Fidler, H. Randolph Byers, Bert L. Vallée and Kurt Olson and has published in prestigious journals such as Science, Proceedings of the National Academy of Sciences and The Journal of Immunology.
In The Last Decade
Marc E. Key
30 papers receiving 3.0k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Marc E. Key United States | 16 | 1.6k | 861 | 527 | 433 | 372 | 31 | 3.2k | ||
| Göran Key Germany | 14 | 1.4k 0.9× | 970 1.1× | 335 0.6× | 472 1.1× | 252 0.7× | 19 | 3.5k | ||
| Ilan Tsarfaty Israel | 32 | 1.8k 1.2× | 967 1.1× | 483 0.9× | 405 0.9× | 434 1.2× | 74 | 3.4k | ||
| Richard C. Bates United States | 32 | 2.2k 1.4× | 1.6k 1.8× | 568 1.1× | 566 1.3× | 356 1.0× | 51 | 4.3k | ||
| Jan Hein van Dierendonck Netherlands | 19 | 1.3k 0.9× | 590 0.7× | 279 0.5× | 321 0.7× | 172 0.5× | 39 | 2.4k | ||
| Chester A. Meyers United States | 25 | 2.2k 1.4× | 688 0.8× | 333 0.6× | 362 0.8× | 199 0.5× | 46 | 3.9k | ||
| C. R. Taylor United States | 21 | 843 0.5× | 500 0.6× | 409 0.8× | 185 0.4× | 341 0.9× | 44 | 2.2k | ||
| Maureen D. O'Connor‐McCourt Canada | 36 | 3.3k 2.1× | 967 1.1× | 384 0.7× | 570 1.3× | 544 1.5× | 118 | 4.6k | ||
| Judith P. Johnson Germany | 31 | 1.8k 1.1× | 1.0k 1.2× | 1.3k 2.4× | 367 0.8× | 622 1.7× | 67 | 3.6k | ||
| Linda H. Shapiro United States | 34 | 2.0k 1.3× | 1.6k 1.8× | 633 1.2× | 587 1.4× | 247 0.7× | 69 | 4.3k | ||
| G. W. H. Stamp United Kingdom | 24 | 942 0.6× | 718 0.8× | 684 1.3× | 215 0.5× | 150 0.4× | 52 | 2.5k |
Countries citing papers authored by Marc E. Key
Since
Specialization
Citations
This map shows the geographic impact of Marc E. Key's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marc E. Key with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marc E. Key more than expected).
Fields of papers citing papers by Marc E. Key
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Marc E. Key. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marc E. Key. The network helps show where Marc E. Key may publish in the future.
Co-authorship network of co-authors of Marc E. Key
This figure shows the co-authorship network connecting the top 25 collaborators of Marc E. Key. A scholar is included among the top collaborators of Marc E. Key based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marc E. Key. Marc E. Key is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Key, Marc E., et al.. (2025). RIG-I and cGAS mediate antimicrobial and inflammatory responses of primary osteoblasts and osteoclasts to Staphylococcus aureus. mBio. 16(5). e0397124–e0397124.
2.
Gupta, Bipin Kumar, George P. Yang, Olga Petrauskene, & Marc E. Key. (2022). Recent Advances in Chromogens for Immunohistochemistry. Methods in molecular biology. 2593. 35–50.
3.
Key, Marc E., et al.. (2019). A Look into Obstructive Sleep Apnea among Ethiopians. Ethiopian Journal of Health Sciences. 29(5). 585–590.
4.
Olson, Karen A., H. Randolph Byers, Marc E. Key, & James W. Fett. (2002). Inhibition of prostate carcinoma establishment and metastatic growth in mice by an antiangiogenin monoclonal antibody. International Journal of Cancer. 98(6). 923–929.
5.
Kao, Richard Yi Tsun, Jeremy L. Jenkins, Karen A. Olson, et al.. (2002). A small-molecule inhibitor of the ribonucleolytic activity of human angiogenin that possesses antitumor activity. Proceedings of the National Academy of Sciences. 99(15). 10066–10071.
6.
Key, Marc E.. (2002). Trends in Immunohistochemistry: The Integration of Tissue-Based Analysis and Molecular Profiling. Journal of Histotechnology. 25(4). 243–245.
7.
Shi, Shan‐Rong, Marc E. Key, & Krishan L. Kalra. (1991). Antigen retrieval in formalin-fixed, paraffin-embedded tissues: an enhancement method for immunohistochemical staining based on microwave oven heating of tissue sections.. Journal of Histochemistry & Cytochemistry. 39(6). 741–748.
8.
Fett, James W., et al.. (1986). Immunocytochemical and enzymatic detection of lysozyme in human colon carcinoma cell lines. Cellular and Molecular Life Sciences. 42(10). 1159–1162.
9.
Lobb, Roy R., Marc E. Key, Edward M. Alderman, & James W. Fett. (1985). Partial purification and characterization of a vascular permeability factor secreted by a human colon adenocarcinoma cell line. International Journal of Cancer. 36(4). 473–478.
10.
Key, Marc E., Herbert Hoover, & Michael G. Hanna. (1985). Active Specific Immunotherapy as an Adjunct to the Treatment of Metastatic Solid Tumors: Present and Future Prospects. PubMed. 1. 195–219.
11.
Key, Marc E., J.S. Brandhorst, & Michael G. Hanna. (1983). Synergistic effects of active specific immunotherapy and chemotherapy in guinea pigs with disseminated cancer.. The Journal of Immunology. 130(6). 2987–2992.
12.
Key, Marc E., James E. Talmadge, William E. Fogler, C D Bucana, & Isaiah J. Fidler. (1982). Isolation of Tumoricidal Macrophages From Lung Melanoma Metastases of Mice Treated Systemically With Liposomes Containing a Lipophilic Derivative of Muramyl Dipeptide<xref ref-type="fn" rid="fn2">2</xref><xref ref-type="fn" rid="fn3">3</xref><xref ref-type="fn" rid="fn4">4</xref>. JNCI Journal of the National Cancer Institute. 69(5). 1198–98.
13.
Key, Marc E., James E. Talmadge, & I. J. Fidler. (1982). Lack of correlation between the progressive growth of spontaneous metastases and their content of infiltrating macrophages.. PubMed. 32(5). 387–96.
14.
Key, Marc E. & Michael G. Hanna. (1982). Antigenic heterogeneity of the guinea pig line 10 hepatocarcinoma. Implications for active specific immunotherapy. Cancer Immunology Immunotherapy. 12(3). 211–215.
15.
Hanna, Michael G. & Marc E. Key. (1982). Immunotherapy of Metastases Enhances Subsequent Chemotherapy. Science. 217(4557). 367–369.
16.
Key, Marc E. & J. S. Haskill. (1981). Immunohistologic evidence for the role of antibody and macrophages in regression of the murine T1699 mammary adenocarcinoma. International Journal of Cancer. 28(2). 225–236.
17.
Key, Marc E. & Mary Hanna. (1981). Mechanism of Action of BCG-Tumor Cell Vaccines in the Generation of Systemic Tumor Immunity. I. Synergism Between BCG and Line 10 Tumor Cells in the Induction of an Inflammatory Response<xref ref-type="fn" rid="FN2">2</xref><xref ref-type="fn" rid="FN3">3</xref>. JNCI Journal of the National Cancer Institute. 67(4). 853–61.
18.
Key, Marc E. & Stephen Haskill. (1981). Macrophage-Mediated, Antibody-Dependent Destruction of Tumor Cells in DBA/2 Mice: In Vitro Identification of an In Situ Mechanism<xref ref-type="fn" rid="fn2">2</xref>, <xref ref-type="fn" rid="fn3">3</xref>. JNCI Journal of the National Cancer Institute. 66(1). 103–10.
19.
Key, Marc E. & M. G. Hanna. (1981). Mechanism of Action of BCG-Tumor Cell Vaccines in the Generation of Systemic Tumor Immunity. II. Influence of the Local Inflammatory Response on Immune Reactivity<xref ref-type="fn" rid="FN2">2</xref><xref ref-type="fn" rid="FN3">3</xref>. JNCI Journal of the National Cancer Institute. 67(4). 863–9.
20.
Talmadge, James E., Marc E. Key, & Ian R. Hart. (1981). Characterization of a murine ovarian reticulum cell sarcoma of histiocytic origin.. PubMed. 41(4). 1271–80.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Göran Key Breakdown of academic impact, for papers by Ilan Tsarfaty Breakdown of academic impact, for papers by Richard C. Bates Breakdown of academic impact, for papers by Jan Hein van Dierendonck Breakdown of academic impact, for papers by Chester A. Meyers Breakdown of academic impact, for papers by C. R. Taylor Breakdown of academic impact, for papers by Maureen D. O'Connor‐McCourt Breakdown of academic impact, for papers by Judith P. Johnson Breakdown of academic impact, for papers by Linda H. Shapiro Breakdown of academic impact, for papers by G. W. H. Stamp